Do you want to read an article? Please log in or register.
Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients
Skin Cancer
Related content
Skin Cancer
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
Eur J Cancer
Boutros A, Taylor AM, Li I, Adegoke NA, Wong T, Varey AHR, Shannon KF, Ch'ng S, Saw RPM, Pennington T, Stretch J, Spillane A, van Akkooi ACJ, Scolyer RA, Pires da Silva I, Carlino MS, Long GV, Lo SN, Menzies AM
doi: 10.1016/j.ejca.2025.115782
Skin Cancer
Predictive value of [(18)F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands
Eur J Cancer
Wilson MJ, Schurink AW, Schrage Y, Wouters MWJM, van Houdt WJ, Grunhagen DJ, van Thienen HV, van de Wiel BA, van der Hiel B, Kuijpers AMJ
doi: 10.1016/j.ejca.2026.116691
Skin Cancer
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Eur J Cancer
Albrecht LJ, Garnier J, Zaremba A, Brauch L, Brunnert F, Rauschenberg R, Forschner A, Vazquez XG, Mangana J, Erdmann M, Angela Y, Franklin C, Tietze J, Lodde G, Tasdogan A, Seier JA, Roesch A, Ugurel S, Berking C, Gutzmer R, Heinzerling L, Meier F, Mohr P, Hassel JC, Schadendorf D, Livingstone E, Zimmer L
doi: 10.1016/j.ejca.2026.116595
Lung, Respiratory and Thoracic Cancer
Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO
JTO Clin Res Rep
Falchero L, Amrane K, Godbert B, Leterre B, Madelaine J, Fournel P, Mascaux C, Raimbourg J, Schneider S, Swalduz A, Veillon R, Langlais A, Missy P, Morin F, Westeel V, Girard N
doi: 10.1016/j.jtocrr.2026.100964
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
Gastrointestinal Cancer
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data
Clin Cancer Res
Campani C, Shim JH, Bouattour M, Touchefeu Y, Delhoume V, Rosmorduc O, Pascale A, An J, Lee HC, Regnault H, Thabut D, Amaddeo G, Ningarhari M, Ollivier-Hourmand I, Métivier C, Ronot M, Ntandaja-Wandji L, Ozenne V, Sidali S, Marra F, Hollande C, Ganne-Carrié N, Nahon P, Peron JM, Lequoy M, Sharma R, Liver Cancer Group P, Allaire M, Nault JC
doi: 10.1158/1078-0432.CCR-25-4943
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapy
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Eur J Surg Oncol
Abdelnour-Berchtold E, Chriqui LE, Zermatten L, Papadopoulos S, Forster C, Hasenauer A, Bedat B, Zellweger M, Kinj R, Mederos N, Christodoulou M, Addeo A, Triponez F, Karenovics W, Gonzalez M, Krueger T, Peters S, Bouchaab H, Perentes JY
doi: 10.1016/j.ejso.2026.111401
Leukemia
Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study
Br J Haematol
Costa A, Scalzulli E, Carmosino I, Bisegna ML, Laganà A, Ielo C, Cappelli L, Martelli M, Breccia M
doi: 10.1111/bjh.70418
Lung, Respiratory and Thoracic Cancer
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
Lung Cancer
Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C
doi: 10.1016/j.lungcan.2025.108583